Answers are grounded in this paper and cite their sources.
High expression of MYC and its target genes identify germinal center B-cell diffuse large B-cell lymphomas (GCB-DLBCL) associated with poor outcomes. We used CRISPR-interference profiling of human lymphoma cell lines to define essential enhancers in the MYC locus and non-immunoglobulin rearrangement partner loci, including a recurrent rearrangement between MYC and the BCL6 locus control region. GCB-DLBCL cell lines without MYC rearrangement were dependent on an evolutionarily conserved enhancer we name “GC B cell MYC enhancer 1,” which was found to be activated by the transcription factor complex of OCT2, OCA-B, and MEF2B, showed an active chromatin state in normal human and mouse GC B cells, and demonstrated selective acetylation and MYC promoter topological interactions in MYC-intact GCB-DLBCL biopsies. Whole-genome sequencing identified tandem copy gains of GC MYC enhancer 1 as a rare but recurrent event in DLBCL. Our findings shed new light on mechanisms that dysregulate MYC, a key driver of B-cell malignancy. Significance: Aberrant MYC activity defines the most aggressive GCB-DLBCLs. We characterized a mechanism of MYC transcriptional activation via a native enhancer that is active in MYC-intact GCB-DLBCL, establishing fitness-sustaining cis- and trans-regulatory circuitry in GCB-DLBCL models that lack MYC enhancer-hijacking rearrangement. See related commentary by Mulet-Lazaro and Delwel, p. 149
No takes yet. Share an insight, caveat, or question.
Iyer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: